Abstract: The invention relates to a product for the release of highly lipophilic physiologically active substances, comprising a core and a coating on top of the core, the coating comprising one or more highly lipophilic physiologically active substances, one or more water-soluble film-forming agents and, relative to the weight of all components, not more than 20 wt % of other auxiliary substances.

Abstract: The invention relates to a solid dosage form that comprises a matrix with one or more highly lipophilic physiologically active substances, one or more water-soluble binders and, relative to the weight of all components, not more than 20 wt % of other auxiliary substances, wherein a physiologically active substance being highly lipophilic if it has a log P of 4 or more.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS). Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from COVID-19, a disease caused by the coronavirus SARS-Cov-2. Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from COVID-19.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from COVID-19, a disease caused by the coronavirus SARS-Cov-2. Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from COVID-19.

Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS). Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.

Abstract: A process for the continuous production of an active ingredient granulate is provided, which comprises the following steps: (a) preparing a spray composition by dissolving or dispersing an active ingredient and optionally one or more excipients in a liquid; (b) providing solid particles in a process space; (c) introducing droplets of the spray composition into an injection zone of the process space in which the liquid evaporates; (d) repeated guiding of the solid particles past the sprayed droplets in the process space with the aid of a process gas jet, so that at least a portion of the droplets, which may have already lost part of the liquid contained, comes into contact with solid particles and larger solid particles are formed through agglomeration; (e) removing the active ingredient granulate from the process space in the form of solid particles, wherein the active ingredient comprises metformin or an acid addition salt of metformin, in particular metformin hydrochloride.

Abstract: A method for the continuous production of an active ingredient granulate is provided, which comprises the following steps: (a) preparing a spray composition by dissolving or dispersing an active ingredient and optionally one or more excipients in a liquid; (b) providing solid particles in a process space; (c) introducing droplets of the spray composition into an injection zone of the process space in which the liquid evaporates; (d) repeatedly guiding the solid particles back past the sprayed droplets in the process space with the aid of a process gas jet, so that at least a portion of the droplets, which may have already lost part of the liquid contained, comes into contact with solid particles and larger solid particles are formed through agglomeration; (e) removing the active ingredient granulate from the process space in the form of solid particles, wherein the active ingredient in the form used has a Hausner factor of 1.19 or greater.

Abstract: A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour.

Abstract: The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in the human body.

Abstract: A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between 3 and 25 wt. % per hour. The active substance is a metoprolol salt.

Abstract: The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in the human body.

Abstract: A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour.

Abstract: An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients.

Abstract: The invention relates to pellets containing a pharmaceutical substance with a breaking strength of more than 0.001 newton, method of production thereof and pharmaceutical preparations based on said pellets.

Abstract: Abstract Oral preparation with controlled release A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between and 25 wt. % per hour. The active substance is a metoprolol salt.